ExcepGen Analysis: $4.0M Raised
What is ExcepGen?
ExcepGen specializes in RNA-based therapeutics that modulate cellular responses to improve tolerability. Their RNAx platform uniquely dampens excessive innate immune responses, setting them apart in the nucleic acid vaccine field. This innovation aims to enhance the safety and effectiveness of RNA medicines, ultimately improving human health.
HQ Country
San Francisco, United States
Employees
1-10
Founded
2018
Industry
Biotech, HealthTech
Product Features & Capabilities
- RNAx platform for modulating cellular responses
- Self-amplifying mRNA vaccines
- Trans-amplifying mRNA vaccines
- mRNA vaccines
- Research publications on RNA therapeutics
How much ExcepGen raised
Seed - $4 million
August 2023Lead Investor: RA Capital Management, Gravity Fund, Apollo Projects (Sam Altman)
